Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells

V. L. Greenberg, J. M. Williams, E. Boghaert, M. Mendenhall, K. B. Ain, S. G. Zimmer

Research output: Contribution to journalArticlepeer-review

18 Scopus citations

Abstract

Anaplastic thyroid carcinoma (ATC) is the most malignant and aggressive form of thyroid cancer. Most patients die within months of diagnosis, primarily due to the absence of effective chemotherapeutic strategies. Identifying alternative therapies is necessary to increase long-term survival. Butyrate elicits a number of responses from cancer cells both in vitro and in vivo including growth repression, cell cycle arrest, differentiation, and apoptosis. Even though many types of cancer cells have been studied, little is known of the response of ATC cells to this drug. In this study, we report that butyrate induces differential cell cycle arrest (arrest in G1 and G2/M phases) in an ATC cell line that correlates with changes in the expression, phosphorylation, and activity of key components of the cell cycle machinery. Exposure to butyrate increases the expression of the cyclin-dependent kinase inhibitors, p21/Cip1 and p27/Kip1, decreases the expression of cyclin A and cyclin B, inhibits the phosphorylation of the retinoblastoma protein (pRb), and decreases the activity of cdk1 and cdk2associated kinases. These results suggest that butyrate may be useful in the clinical treatment of ATC.

Original languageEnglish
Pages (from-to)21-29
Number of pages9
JournalThyroid
Volume11
Issue number1
DOIs
StatePublished - 2001

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Fingerprint

Dive into the research topics of 'Butyrate alters the expression and activity of cell cycle components in anaplastic thyroid carcinoma cells'. Together they form a unique fingerprint.

Cite this